PT - JOURNAL ARTICLE AU - Gonché Danesh AU - Baptiste Elie AU - Yannis Michalakis AU - Mircea T Sofonea AU - Antonin Bal AU - Sylvie Behillil AU - Grégory Destras AU - David Boutolleau AU - Sonia Burrel AU - Anne-Geneviève Marcelin AU - Jean-Christophe Plantier AU - Vincent Thibault AU - Etienne Simon-Loriere AU - Sylvie van der Werf AU - Bruno Lina AU - Laurence Josset AU - Vincent Enouf AU - Samuel Alizon AU - the COVID SMIT PSL group TI - Early phylodynamics analysis of the COVID-19 epidemics in France AID - 10.1101/2020.06.03.20119925 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.03.20119925 4099 - http://medrxiv.org/content/early/2020/06/04/2020.06.03.20119925.short 4100 - http://medrxiv.org/content/early/2020/06/04/2020.06.03.20119925.full AB - France was one of the first countries to be reached by the COVID-19 pandemics. Here, we analyse 196 SARS-Cov-2 genomes collected between Jan 24 and Mar 24 2020, and perform a phylodynamics analysis. In particular, we analyse the doubling time, reproduction number (ℛt) and infection duration associated with the epidemic wave that was detected in incidence data starting from Feb 27. We show that a slowing down of the epidemic spread can be detected in Mar, which is consistent with the implementation of the national lock-down on Mar 17. The inferred distributions for the infection duration and ℛt are in line with those estimated from contact tracing data. Overall, this analysis shows the potential to use sequence genomic data to inform public health decisions in an epidemic crisis context.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGonche Danesh is supported by a doctoral grant from the Fondation pour la Recherche Medicale (FRM grant number ECO20170637560). No other external funding was available for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We follow the GISAID agreement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences data originated from the Global Initiative on Sharing All Influenza Data (GISAID, https://www.gisaid.org/) and are listed in Appendix Table S1. https://platform.gisaid.org/